Localized follicular lymphomas: Prognosis and survival of stages I and II in a retrospective series of 103 patients

Soubeyran, Pierre; Eghbali, Houchingue; Bonichon, F.; Coindre, Jean Michél; Richaud, Pierre; Hoerni, B

doi:10.1016/0167-8140(88)90030-8

Cited by 33 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most studies in the literature reject the idea of extended OS as a result of chemotherapy [2,13,18,27], the assessments of its value on RFS are inconsistent. Guadagnolo et al and other authors noted no increase in RFS [13,18,25,26,39], yet two other studies [1,23] did find extended RFS after combined-modality therapy. Yahalom et al reported increased RFS after combination therapy in a patient group with intermediate-grade NHLs, but no such improvement could be shown for low-grade NHL patients [43].…”

Section: Time (Years)mentioning

confidence: 89%

Long-Term Outcome and Prognostic Factors in Early-Stage Nodal Low-Grade Non-Hodgkin’s Lymphomas Treated with Radiation Therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Time (Years)mentioning

confidence: 89%

Long-Term Outcome and Prognostic Factors in Early-Stage Nodal Low-Grade Non-Hodgkin’s Lymphomas Treated with Radiation Therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The addition of chemotherapy to local or extended radio-therapy has been reported not to improve results for overall survival or relapse free survival in Stages I or II low-grade NHL [4,22,24,30,45,55].…”

Section: Discussionmentioning

confidence: 99%

Centroblastic-Centrocytic Non-Hodgkin's Lymphoma Stage I–III: Patterns of Failure Following Radiotherapy

Frank¹,

Zierhut²,

Schulz-Ertner³

et al. 2001

Strahlenther Onkol

View full text Add to dashboard Cite

In involved lymph node regions a relatively small number of relapses was observed after application of a minimal dose of 36 Gy. In Stages I/II most relapses were located outside the radiation portals, yet EF-RT was not superior to IF-RT in terms of overall survival and relapse free survival. Prospective randomized trials are necessary to prove a potentially favorable effect of more extended radiotherapy portals (TLI or TNI [total nodal irradiation]) and to evaluate the optimal radiotherapy dose.

show abstract

“…[11][12][13] In patients treated with local RT, prognostic factors predictive of a high risk of relapse included age, stage II disease, systemic symptoms, and tumour bulk. 5,6,8,14 Follicular grade 2 histology was also an adverse factor for relapse in one series. 6 Based on 1795 patients, of whom only about 22% had stage I-II disease, the follicular lymphoma international prognostic index (FLIPI) defined five adverse prognostic factors for survival: age !…”

Section: Stage I-ii Follicular Lymphomamentioning

confidence: 96%

Radiation therapy for localized low-grade non-Hodgkin's lymphomas

Tsang

Gospodarowicz

2005

Hematol. Oncol.

View full text Add to dashboard Cite

The most common low grade B-cell non-Hodgkin's lymphomas are follicular lymphomas, and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas. Localized presentations of follicular lymphoma occur in 20-30% of cases, while for MALT lymphomas, stage I-II disease presentations occur in 70-90%. These are radiation-sensitive lymphomas. Following moderate dose local radiation treatment (30-35 Gy) for these stage I and II low grade lymphomas, the clinical results indicate long-term local control and possible cure. While local control is achieved with minimal morbidity with involved-field radiation therapy, a significant proportion of patients relapse with systemic disease outside of radiation fields. For follicular lymphoma, this occurs in approximately 50% of patients after 15 years, and for non-gastric MALT lymphoma, 30-40% after 10 years. Although patients with relapsed systemic disease are not curable with chemotherapy, the disease often behaves in an indolent fashion and prolonged survival is observed. For gastric MALT lymphomas, radiation therapy is indicated in patients whose lymphoma did not respond to Helicobacter pylori eradication therapy, or in gastric lymphoma not related to this microorganism. The subject of causative agents responsible for non-gastric MALT lymphomas is under active study and the identification of putative microorganisms will lead to improved treatment strategies for these unusual lymphomas, similar to the success in gastric lymphomas over the last decade.

show abstract

Localized follicular lymphomas: Prognosis and survival of stages I and II in a retrospective series of 103 patients

Cited by 33 publications

References 26 publications

Long-Term Outcome and Prognostic Factors in Early-Stage Nodal Low-Grade Non-Hodgkin’s Lymphomas Treated with Radiation Therapy

Long-Term Outcome and Prognostic Factors in Early-Stage Nodal Low-Grade Non-Hodgkin’s Lymphomas Treated with Radiation Therapy

Centroblastic-Centrocytic Non-Hodgkin's Lymphoma Stage I–III: Patterns of Failure Following Radiotherapy

Radiation therapy for localized low-grade non-Hodgkin's lymphomas

Contact Info

Product

Resources

About